Drug Trial Radar · NCT05909488
Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II
Last checked: Nov 20, 2026Latest source record: Feb 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
May 2026
Primary completion
Jul 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- PT. Prodia Stem Cell IndonesiaIndustry
- Sponsor type
- Industry
- First posted
- Jun 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will perform UC-MSCs and CM transplantation. There are two groups with different dosages. The first group will be transplanted with 1.5 million cells, meanwhile, the second group is 5 million cells. Each group consists of 30 subjects. All groups will be transplanted via the peribulbar route. All groups will be observed until six months.
Conditions
- Retinitis Pigmentosa
Interventions
1.5 x 10^6 UC-MSC + CMBiological
1.5 million cells of UC-MSC in 2 ml of Conditioned Medium (CM)
5 x 10^6 UC-MSC + CMBiological
5 million cells of UC-MSC in 2 ml of Conditioned Medium (CM)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incident of Adverse EventsTime frame: 1 day after injection
- Incident of Adverse EventsTime frame: 1 week after injection
- Frequency of Adverse EventsTime frame: 1 day after injection
- Frequency of Adverse EventsTime frame: 1 week after injection
- Visual Acuity TestTime frame: 1 week after injection
- Visual Acuity TestTime frame: 1 month after injection
- Visual Acuity TestTime frame: 3 months after injection
- Visual Acuity TestTime frame: 6 months after injection
- Visual Field TestTime frame: 1 week after injection
- Visual Field TestTime frame: 1 month after injection
- Visual Field TestTime frame: 3 months after injection
- Visual Field TestTime frame: 6 months after injection
- FunduscopyTime frame: 1 week after injection
- FunduscopyTime frame: 1 month after injection
- FunduscopyTime frame: 3 months after injection
- FunduscopyTime frame: 6 months after injection
- ElectrorectinographyTime frame: 1 week after injection
- ElectrorectinographyTime frame: 1 month after injection
- ElectrorectinographyTime frame: 3 months after injection
- ElectrorectinographyTime frame: 6 months after injection
- Optical Coherence Tomography (OCT)Time frame: 1 week after injection
- Optical Coherence Tomography (OCT)Time frame: 1 month after injection
- Optical Coherence Tomography (OCT)Time frame: 3 months after injection
- Optical Coherence Tomography (OCT)Time frame: 6 months after injection
Locations
1 site in 1 country. Site status is shown where the registry gives one.
RSUP Dr. Sardjito
Yogyakarta, DI Yogyakarta, Indonesia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.